EPISODE · Feb 23, 2026 · 5 MIN
Novo's Martin Holst Lange Talks New Weight Loss Shot
from Bloomberg Talks · host Bloomberg
Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger. See omnystudio.com/listener for privacy information.
NOW PLAYING
Novo's Martin Holst Lange Talks New Weight Loss Shot
No transcript for this episode yet
Similar Episodes
Feb 8, 2026 ·26m
Jan 29, 2026 ·39m
Jan 14, 2026 ·25m
Jan 8, 2026 ·7m
Jan 7, 2026 ·45m